E. Ohman J or Asset Management AB Invests $7.72 Million in Abbott Laboratories $ABT

E. Ohman J or Asset Management AB purchased a new stake in shares of Abbott Laboratories (NYSE:ABT) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 61,637 shares of the healthcare product maker’s stock, valued at approximately $7,722,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Norges Bank bought a new stake in Abbott Laboratories during the 2nd quarter valued at $3,026,180,000. Laurel Wealth Advisors LLC grew its position in shares of Abbott Laboratories by 13,347.0% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 6,056,934 shares of the healthcare product maker’s stock worth $823,804,000 after buying an additional 6,011,891 shares in the last quarter. Invesco Ltd. increased its stake in shares of Abbott Laboratories by 51.0% during the third quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock valued at $1,868,718,000 after buying an additional 4,713,135 shares during the period. First Trust Advisors LP increased its stake in shares of Abbott Laboratories by 180.7% during the second quarter. First Trust Advisors LP now owns 3,063,443 shares of the healthcare product maker’s stock valued at $416,659,000 after buying an additional 1,972,097 shares during the period. Finally, Alliancebernstein L.P. raised its holdings in shares of Abbott Laboratories by 51.0% in the third quarter. Alliancebernstein L.P. now owns 5,525,906 shares of the healthcare product maker’s stock valued at $740,140,000 after acquiring an additional 1,865,250 shares in the last quarter. Institutional investors own 75.18% of the company’s stock.

Wall Street Analysts Forecast Growth

ABT has been the topic of several recent research reports. Argus dropped their target price on shares of Abbott Laboratories from $150.00 to $140.00 in a report on Tuesday, January 27th. Leerink Partners lowered their price target on shares of Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a research report on Friday, January 30th. Piper Sandler dropped their price objective on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a research note on Friday, January 23rd. Freedom Capital raised shares of Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 29th. Finally, Citigroup lowered their target price on Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating for the company in a report on Wednesday, March 11th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $136.16.

Abbott Laboratories Stock Performance

ABT stock opened at $104.87 on Tuesday. Abbott Laboratories has a one year low of $104.10 and a one year high of $139.06. The firm has a market cap of $182.65 billion, a price-to-earnings ratio of 28.19, a PEG ratio of 1.68 and a beta of 0.74. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58. The firm has a 50-day simple moving average of $112.36 and a two-hundred day simple moving average of $122.77.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The firm had revenue of $11.46 billion for the quarter, compared to the consensus estimate of $11.80 billion. During the same quarter in the previous year, the firm earned $1.34 EPS. The company’s quarterly revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, equities analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.4%. Abbott Laboratories’s dividend payout ratio is presently 67.74%.

Insider Activity

In related news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the company’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $102,288.30. Following the transaction, the executive vice president directly owned 146,377 shares of the company’s stock, valued at $16,918,253.66. This represents a 0.60% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, VP John A. Jr. Mccoy sold 585 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $67,614.30. Following the completion of the sale, the vice president directly owned 24,628 shares of the company’s stock, valued at approximately $2,846,504.24. This represents a 2.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 3,055 shares of company stock worth $353,097. Company insiders own 0.46% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.